Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV000779854 | SCV000916716 | likely pathogenic | Hereditary breast ovarian cancer syndrome | 2018-02-22 | criteria provided, single submitter | clinical testing | Variant summary: BRCA1 c.2295delG (p.Ser766ValfsX26) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (eg. c.2299delA (p.Ser767fsX25), c.2338C>T (p.Gln780X), c.2389G>T (p.Glu797X)). The variant was absent in 245858 control chromosomes. To our knowledge, no occurrence of c.2295delG in individuals affected with Hereditary Breast and Ovarian Cancer and no experimental evidence demonstrating its impact on protein function have been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic. |
| Invitae | RCV000779854 | SCV001588990 | pathogenic | Hereditary breast ovarian cancer syndrome | 2023-10-04 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Ser766Valfs*26) in the BRCA1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA1 are known to be pathogenic (PMID: 20104584). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with breast and/or ovarian cancer (PMID: 30555256). ClinVar contains an entry for this variant (Variation ID: 632678). For these reasons, this variant has been classified as Pathogenic. |
| Ambry Genetics | RCV002458393 | SCV002737643 | pathogenic | Hereditary cancer-predisposing syndrome | 2022-03-17 | criteria provided, single submitter | clinical testing | The c.2295delG variant, located in coding exon 9 of the BRCA1 gene, results from a deletion of one nucleotide at nucleotide position 2295, causing a translational frameshift with a predicted alternate stop codon (p.S766Vfs*26). This alteration was identified in a cohort of 206 unrelated breast and/or ovarian cancer cases from North India who met NCCN guidelines for genetic testing (Mehta A et al. Cancer Manag Res, 2018 Nov;10:6505-6516). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |